Cuál es el precio por Corvus Pharmaceuticals, Inc. (CRVS)

Precio por Corvus Pharmaceuticals, Inc. (CRVS) es de$14.07

Cuál es la capitalización de mercado por Corvus Pharmaceuticals, Inc. (CRVS)

Capitalización de mercado por Corvus Pharmaceuticals, Inc. (CRVS) es $1.18B

Corvus Pharmaceuticals, Inc. (CRVS) Ratio P/S

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

Año	Ratio P/S	Cambiar
Not enough data for the provided dates.

Año

Ratio P/S

Cambiar

Not enough data for the provided dates.

Empresa	Ratio P/S	Diferencia del ratio P/S	País
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Moderna, Inc. MRNA.US	11.28	-	US
Lonza Group AG LONN.SW	-	-	CH

Empresa

Ratio P/S

Diferencia del ratio P/S

País